• / Free eNewsletters & Magazine
  • / My Account
Home>OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis

OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis

3party Content

Sat, 30 May 2015

OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.